24 Feb 2010 15:31
PLETHORA SOLUTIONS HOLDINGS PLC
("Plethora" or the "Company")
Holdings in Company
Plethora, the specialist developer of products for the treatment and management of urological disorders has today been notified that as a result of recent purchases, Helium Special Situations Fund now holds 2,136,594 ordinary shares of 1 pence each in the Company, representing approximately 5.1% of the Company's current issued share capital.
Enquiries:
Plethora Solutions
Steven Powell Tel : +44(0) 20 3077 5400
FinnCap
Geoff Nash/Marc Young Tel : +44(0) 20 7600 1658
Hansard Group
Adam Reynolds/John Bick Tel: +44(0) 20 7245 1100
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510) and premature ejaculation (PSD502). Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of therapeutic products for the management and treatment of urology, andrology and obstetric conditions.The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE)
Further information is available at www.plethorasolutions.co.uk
Plethora Solutions Holdings Plc (PLE)